Who are Fengshigutong Capsule plus Imrecoxib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fengshigutong-capsule-plus-imrecoxib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fengshigutong Capsule plus Imrecoxib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fengshigutong Capsule plus Imrecoxib (Fengshigutong Capsule plus Imrecoxib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 inhibitor combined with herbal anti-inflammatory. Area: Rheumatology / Musculoskeletal.

marketed COX-2 inhibitor combined with herbal anti-inflammatory COX-2 (cyclooxygenase-2) Rheumatology / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

Fengshigutong Capsule plus Imrecoxib (Fengshigutong Capsule plus Imrecoxib) — Sun Yat-sen University. This combination product combines traditional Chinese medicine (Fengshigutong) with Imrecoxib, a selective COX-2 inhibitor, to reduce inflammation and pain in joint and musculoskeletal conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fengshigutong Capsule plus Imrecoxib TARGET	Fengshigutong Capsule plus Imrecoxib	Sun Yat-sen University	marketed	COX-2 inhibitor combined with herbal anti-inflammatory	COX-2 (cyclooxygenase-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 inhibitor combined with herbal anti-inflammatory class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fengshigutong Capsule plus Imrecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/fengshigutong-capsule-plus-imrecoxib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab